Nedjad Losic
Corporate Officer/Principal at CANTARGIA AB
Net worth: 7 826 $ as of 2024-04-29
Network origin in Nedjad Losic first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
19
| Public Company | Pharmaceuticals: Major | 19 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Nedjad Losic via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| University of Lund | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal Graduate Degree Graduate Degree | |
| ACTIVE BIOTECH AB | Biotechnology | Investor Relations Contact Corporate Officer/Principal | |
| MENDUS AB | Biotechnology | Director/Board Member Director/Board Member | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree | |
| Lisa Martin-Löf Konsultbyrå AB | Director/Board Member | ||
| WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director of Finance/CFO | |
| Sciencecap Stockholm AB | Director/Board Member | ||
Extenda AB
 Extenda AB Information Technology ServicesTechnology Services Extenda AB develops point-of-sale technology (POS) solutions. Its product suite include transaction engine, selfscan, mobile POS, and self checkout. The firm also offers support, service and maintenance, and catalogue services. The company was founded by Peter Carlman in 1982 and is headquartered in Stockholm, Sweden. | Information Technology Services | Director of Finance/CFO | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Investor Relations Contact | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director of Finance/CFO | |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| Oncopeptides Incentive AB | Director/Board Member | ||
| University of Stockholm | College/University | Undergraduate Degree | |
| BIOARCTIC AB | Pharmaceuticals: Major | Director of Finance/CFO | |
A3P Biomedical AB
 A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Medical/Nursing Services | Director of Finance/CFO | |
| QLUCORE AB | Packaged Software | Founder | |
| Neodos AB | Director/Board Member | ||
| COEGIN PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
| ENSIMAG | College/University | Graduate Degree | |
| VITROLIFE AB | Medical Specialties | Chief Executive Officer | |
Isogenica Ltd.
 Isogenica Ltd. Miscellaneous Commercial ServicesCommercial Services Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| RAYSEARCH LABORATORIES AB | Packaged Software | Director of Finance/CFO | |
| CAMURUS AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cytoseek Ltd.
 Cytoseek Ltd. Miscellaneous Commercial ServicesCommercial Services Cytoseek Ltd. provides cell membrane augmentation technology for enhancement of cell therapies for cancer, heart disease, osteoarthritis, and diabetic wound healing. It enables new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. The company was founded by Adam Willis Perriman on November 22, 2017 and is headquartered in Bristol, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
Pepgen Ltd.
 Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Packaged Software | Chairman | |
Imophoron Ltd.
 Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | Biotechnology | Chairman | |
| Treehill Partners, LLC | Corporate Officer/Principal | ||
| CIRCIO HOLDING ASA | Biotechnology | Chairman | |
Resolys Bio, Inc.
 Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY. | Miscellaneous Commercial Services | Director/Board Member | |
| Theralpha | Director/Board Member | ||
Agalimmune Ltd.
 Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Part of BioLineRx Ltd., Agalimmune Ltd. is a British company that develops anti-cancer immunotherapy technology. The private company is based in London, UK. The company was founded by Charles Campbell Roberts and Graham Griffiths. The CEO is Mike Westby. Agalimmune was acquired by BioLineRx Ltd. on March 23, 2017 for $6.05 million. | Pharmaceuticals: Major | Director/Board Member | |
Loxbridge Research LLP
 Loxbridge Research LLP Financial ConglomeratesFinance Loxbridge Research LLP operates as an investment and project management company. It specializes in startup, early stage, and later stage investments in growth stage companies. The firm supports scientists and focuses on sectors like science, medicine and healthcare technology particularly biotech, med-tech, noval therapeutic, diagnostics, cancer, infectious diseases, neurodegeneration, imaging hardware and software, and enabling devices. The company was founded by Charles Roberts in 2008 and is headquartered in London, the United Kingdom. | Financial Conglomerates | Director/Board Member | |
| NICOX SA | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Royal Institute of Technology | College/University | Graduate Degree | |
Active Biotech Research AB
 Active Biotech Research AB Pharmaceuticals: MajorHealth Technology Active Biotech Research AB develops pharmaceuticals. The private company is based in Lund, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| Active Security Trading AB | Director/Board Member | ||
| University of Geneva | College/University | Doctorate Degree | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Real Estate Development | Corporate Officer/Principal | |
| VIRACTA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Università degli Studi di Modena e Reggio Emilia | College/University | Doctorate Degree | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Lausanne | College/University | Masters Business Admin | |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Pharmaceuticals: Generic | Chief Executive Officer | |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Universidad Autónoma de Madrid | College/University | Doctorate Degree |
Statistics
International
| Sweden | 26 |
| United Kingdom | 8 |
| United States | 6 |
| Switzerland | 6 |
| France | 4 |
Sectoral
| Health Technology | 24 |
| Consumer Services | 10 |
| Technology Services | 5 |
| Commercial Services | 5 |
| Finance | 3 |
Operational
| Director/Board Member | 67 |
| Corporate Officer/Principal | 30 |
| Chairman | 22 |
| Independent Dir/Board Member | 22 |
| Chief Executive Officer | 12 |
Most connected contacts
- Stock Market
- Insiders
- Nedjad Losic
- Company connections
